This article is more than 5 years old. Information may no longer be current.

Santen, Glaukos enter MicroShunt distribution agreement

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Glaukos will be the exclusive distributor of Santen’s MicroShunt in the United States, the companies announced.

The multi-year distribution agreement stipulates that Glaukos will be responsible for sales and distribution of the device, pending U.S. approval, while Santen continues to hold responsibility for manufacturing, quality and safety controls, regulatory activities and post-approval marketing requirements. according to a press release.

A minimally invasive ab externo surgical device, the MicroShunt is designed to treat primary open-angle glaucoma and is currently being studied in an FDA pivotal trial for IOP reduction.

“Santen is very excited to partner with Glaukos, whose proven surgical glaucoma expertise and established distribution and sales infrastructure in the United States are unparalleled,” Shigeo Taniuchi, Santen president and chief operating officer, said in the release. “We strongly believe that this partnership will bring MicroShunt, if approved, to physicians and patients in the United States in the most timely, efficient and effective way possible.”

Financial details of the agreement were not disclosed.